Amy King

536 total citations
7 papers, 32 citations indexed

About

Amy King is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology. According to data from OpenAlex, Amy King has authored 7 papers receiving a total of 32 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Biotechnology. Recurrent topics in Amy King's work include Cancer Research and Treatments (4 papers), Occupational and environmental lung diseases (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Amy King is often cited by papers focused on Cancer Research and Treatments (4 papers), Occupational and environmental lung diseases (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Amy King collaborates with scholars based in United Kingdom, Australia and China. Amy King's co-authors include Mary L. Wright, James A. Carr, Peter Wells-Jordan, Anne Thomas, Dean A. Fennell, Liz Darlison, Cassandra Brookes, Charlotte Poile, Amrita Bajaj and Alastair Greystoke and has published in prestigious journals such as Journal of Clinical Oncology and General and Comparative Endocrinology.

In The Last Decade

Amy King

6 papers receiving 31 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy King United Kingdom	4	18	7	6	5	5	7	32
Katherine Bigay United States	2	20 1.1×		3 0.5×			2	31
Isabelle Vuillaume France	3	10 0.6×		5 0.8×			5	32
James Krainson United States	3	26 1.4×	3 0.4×	2 0.3×			4	39
Elijah S. Lawrence United States	3	9 0.5×	16 2.3×				4	47
Marek Turnovec Czechia	4	23 1.3×		3 0.5×			6	41
Diane Masser‐Frye United States	2	5 0.3×		5 0.8×		1 0.2×	3	18
Carme Barberà Spain	3	8 0.4×	2 0.3×				3	21
Bruno Compagnoni Italy	3	8 0.4×		2 0.3×			3	25
Dave Viskochil United States	4	6 0.3×		3 0.5×			4	27
Martin Banchero Netherlands	3	6 0.3×				2 0.4×	6	30

Countries citing papers authored by Amy King

Since Specialization

Citations

This map shows the geographic impact of Amy King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy King more than expected).

Fields of papers citing papers by Amy King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy King. The network helps show where Amy King may publish in the future.

Co-authorship network of co-authors of Amy King

This figure shows the co-authorship network connecting the top 25 collaborators of Amy King. A scholar is included among the top collaborators of Amy King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy King. Amy King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Krebs, Matthew, Amy Branson, Shaun Barber, et al.. (2023). Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.. Journal of Clinical Oncology. 41(16_suppl). 8511–8511. 5 indexed citations

2.

Fennell, Dean A., Amy Branson, Amy King, et al.. (2023). A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma.. Journal of Clinical Oncology. 41(16_suppl). e20534–e20534.

3.

Fennell, Dean A., Amy King, Amy Branson, et al.. (2022). Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4—a phase IIa trial with cellular and molecular correlates of efficacy.. Journal of Clinical Oncology. 40(16_suppl). 8560–8560. 1 indexed citations

4.

Fennell, Dean A., Amy King, Seid Mohammed, et al.. (2021). A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.. Journal of Clinical Oncology. 39(15_suppl). 8558–8558. 7 indexed citations

5.

Fennell, Dean A., Liz Darlison, Peter Wells-Jordan, et al.. (2020). MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.. Journal of Clinical Oncology. 38(15_suppl). 9057–9057. 5 indexed citations

6.

Kidd, Andrew, Laura Miller, Craig Dick, et al.. (2020). Mesothelioma is associated with ipsilateral thoracic muscle loss. 1147–1147. 1 indexed citations

7.

Wright, Mary L., et al.. (2006). Effects of bilateral and unilateral ophthalmectomy on plasma melatonin in Rana tadpoles and froglets under various experimental conditions. General and Comparative Endocrinology. 147(2). 158–166. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact